GB Patent

GB0522932D0 — PKC412 in treatment of atypical chronic myeloid leukemia

Assigned to University of Southampton · Expires 2005-12-21 · 20y expired

What this patent protects

Patent listed against Rydapt.

Drugs covered by this patent

Patent Metadata

Patent number
GB0522932D0
Jurisdiction
GB
Classification
—
Expires
2005-12-21
Drug substance claim
No
Drug product claim
No
Assignee
University of Southampton
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.